ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31
ANGIODYNAMICS INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$11.39+0.15 (+1.33%)
Close on Oct 19, 2026
- Market cap
- $478.63M
- P/E (TTM)
- –
- Dividend yield
- –
ANGIODYNAMICS INC revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Med Device | $170.22M | $165.85M | $197.51M | $242.07M | – | – | – | – | – | – | 53.2% | +2.6% |
| Med Tech | $149.95M | $126.65M | $106.40M | $96.69M | – | – | – | – | – | – | 46.8% | +18.4% |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Med Device | $170.22M | $165.85M | $197.51M | $242.07M | – | – | – | – | – | – | 53.2% | +2.6% |
| Med Tech | $149.95M | $126.65M | $106.40M | $96.69M | – | – | – | – | – | – | 46.8% | +18.4% |
| Oncology/Surgery | – | – | – | – | $55.10M | $54.62M | $57.15M | $56.00M | $49.19M | $44.56M | – | – |
| Vascular Access | – | – | – | – | – | – | $94.30M | $94.73M | $92.76M | $96.48M | – | – |
| Vascular Interventions & Therapies | – | – | – | – | – | – | $112.71M | $119.90M | $119.70M | $128.75M | – | – |
| Vascular Access | – | – | – | – | $100.19M | $101.31M | $94.30M | $94.73M | – | – | – | – |
| Oncology | – | – | – | – | $55.10M | $54.62M | $57.15M | $56.00M | – | – | – | – |
| Endovascular Therapies | – | – | – | – | $160.93M | $135.08M | $112.71M | $119.90M | – | – | – | – |
| Endovascular Therapies | – | – | – | – | $160.93M | $135.08M | $112.71M | $119.90M | – | – | – | – |
| Med Device | – | – | $197.51M | $242.07M | $237.50M | $235.28M | $223.14M | – | – | – | – | – |
| Med Tech | – | – | $106.40M | $96.69M | $78.72M | $55.73M | $41.02M | – | – | – | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $274.92M | $250.98M | $251.49M | $282.71M | $265.96M | $237.04M | $207.98M | $216.96M | $213.73M | $223.82M | 85.9% | +9.5% |
| International | $45.25M | $41.52M | $52.43M | $56.04M | $50.26M | $53.97M | $56.18M | $53.68M | – | – | 14.1% | +9.0% |
| International | – | $41.52M | $52.43M | $56.04M | $50.26M | $53.97M | $56.18M | $53.68M | $47.93M | $45.97M | – | – |
From the segment and revenue-disaggregation notes of Angiodynamics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.